Rxsight vs Blue Sail Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Rxsight Inc (RXST)

Q3 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

July 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Latest6 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Blue Sail Medical Co Ltd (002382.CS)

Q3 202614 Jul – 25 Aug 2026

▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.
The profit turnaround is the central new fact that answers why the stock is moving.
Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.
It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.
Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.
The completed divestment is a new capital event that improves cash and focus.
Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.
It is the real counterweight explaining why profit is much lower than divisional results.

August 202614 Jul – 25 Aug 2026

▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.
The profit turnaround is the central new fact that answers why the stock is moving.
Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.
It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.
Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.
The completed divestment is a new capital event that improves cash and focus.
Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.
It is the real counterweight explaining why profit is much lower than divisional results.

Latest14 Jul – 25 Aug 2026

▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.
The profit turnaround is the central new fact that answers why the stock is moving.
Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.
It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.
Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.
The completed divestment is a new capital event that improves cash and focus.
Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.
It is the real counterweight explaining why profit is much lower than divisional results.